Maxim Group analyst Anthony Vendetti has maintained their neutral stance on JYNT stock, giving a Hold rating on March 14.
Anthony Vendetti has given his Hold rating due to a combination of factors impacting The Joint Corp. While the company has shown improvement in system-wide sales growth and is transitioning to a pure franchisor model, there are still uncertainties surrounding the timeline for the sale of its company-owned clinics. This transition is expected to reduce overall revenue but also decrease corporate expenses, allowing for potential investments in marketing and technology.
Despite the low startup costs attracting new franchisees and the company’s advancements in digital strategy, execution risks remain. The financial impact of these investments is uncertain, and broader macroeconomic challenges could pose additional headwinds. Given these factors, while the strategic shift may offer long-term growth potential, the short-term performance could be volatile, leading to the Hold recommendation.
According to TipRanks, Vendetti is an analyst with an average return of -24.2% and a 24.49% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Daxor, Strata Skin Sciences, and Joint.
In another report released on March 14, Craig-Hallum also reiterated a Hold rating on the stock with a $10.50 price target.